CN110590873B - 一种合欢皮新木脂体化合物 - Google Patents
一种合欢皮新木脂体化合物 Download PDFInfo
- Publication number
- CN110590873B CN110590873B CN201910945573.4A CN201910945573A CN110590873B CN 110590873 B CN110590873 B CN 110590873B CN 201910945573 A CN201910945573 A CN 201910945573A CN 110590873 B CN110590873 B CN 110590873B
- Authority
- CN
- China
- Prior art keywords
- compound
- cells
- huvec
- induced
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 240000007185 Albizia julibrissin Species 0.000 title description 7
- 235000011468 Albizia julibrissin Nutrition 0.000 title description 7
- 229930013686 lignan Natural products 0.000 title description 5
- 235000009408 lignans Nutrition 0.000 title description 5
- -1 lignan compound Chemical class 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 46
- 239000003814 drug Substances 0.000 claims abstract description 18
- 210000002889 endothelial cell Anatomy 0.000 claims abstract description 14
- 229940079593 drug Drugs 0.000 claims abstract description 11
- 208000017170 Lipid metabolism disease Diseases 0.000 claims abstract description 8
- 230000001737 promoting effect Effects 0.000 claims abstract description 8
- 239000007788 liquid Substances 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 230000012292 cell migration Effects 0.000 claims description 5
- 238000013508 migration Methods 0.000 claims description 5
- 230000004663 cell proliferation Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000036542 oxidative stress Effects 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 210000003038 endothelium Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 43
- 239000003642 reactive oxygen metabolite Substances 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 10
- 235000021588 free fatty acids Nutrition 0.000 abstract description 10
- 208000015707 frontal fibrosing alopecia Diseases 0.000 abstract description 10
- 150000002632 lipids Chemical class 0.000 abstract description 8
- 230000007863 steatosis Effects 0.000 abstract description 7
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract description 7
- 230000035755 proliferation Effects 0.000 abstract description 5
- 230000003833 cell viability Effects 0.000 abstract description 4
- 210000003734 kidney Anatomy 0.000 abstract description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 abstract description 2
- 229910052753 mercury Inorganic materials 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 34
- 238000010828 elution Methods 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- 239000012071 phase Substances 0.000 description 15
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 10
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 8
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 230000014759 maintenance of location Effects 0.000 description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 8
- 229910001868 water Inorganic materials 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 5
- 229930182555 Penicillin Natural products 0.000 description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 230000003698 anagen phase Effects 0.000 description 5
- 230000033115 angiogenesis Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 229940049954 penicillin Drugs 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 229960005322 streptomycin Drugs 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 230000003511 endothelial effect Effects 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- 239000007791 liquid phase Substances 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000003606 umbilical vein Anatomy 0.000 description 4
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 3
- 230000005779 cell damage Effects 0.000 description 3
- 208000037887 cell injury Diseases 0.000 description 3
- 239000000287 crude extract Substances 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 150000005692 lignans Chemical class 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 238000000825 ultraviolet detection Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- YSCJAYPKBYRXEZ-HZPINHDXSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4ar,6ar,6bs,8as,12as,14ar,14br)-4,4,6a,6b,11,11,14b-heptamethyl-8a-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3-hydroxy-4-[(2s,3r,4s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C(O)=O)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YSCJAYPKBYRXEZ-HZPINHDXSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000002021 butanolic extract Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- BUBVKRMIMSPLND-UHFFFAOYSA-N (-)-syringaresinol 4-O-beta-D-apiofuranosyl-(1->2)-beta-D-glucopyranoside Natural products COC1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(OC)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)(CO)CO4)O)=C(OC)C=3)CO2)=C1 BUBVKRMIMSPLND-UHFFFAOYSA-N 0.000 description 1
- ITOWTHYPYGRTRL-SYHAXYEDSA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-propoxyoxane-3,4,5-triol Chemical compound CCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ITOWTHYPYGRTRL-SYHAXYEDSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000220433 Albizia Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000021479 Cardiovascular injury Diseases 0.000 description 1
- 241000026010 Dendrobium candidum Species 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000008809 cell oxidative stress Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009707 neogenesis Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004262 preparative liquid chromatography Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/18—Acyclic radicals, substituted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种合欢皮新木脂体化合物,属于生物医药技术领域。本发明制备的化合物在浓度为可有效治疗FFAs诱导的脂代谢紊乱及脂肪变性,在给药浓度为20μM,给药24h可以使脂滴面积减少约3倍;并可显著增强HUVEC的细胞活性,显著促进细胞的自我复制,从而促进内皮细胞HUVEC增殖。在给药40μM,给药24h后,可使细胞活力为达到对照的242.233%。本发明制备的化合物可显著抑制HUVEC细胞因HG诱导的活性氧簇(ROS)的产生,可使HG组平均荧光强度由818.37%降低至176.36%。
Description
技术领域
本发明涉及一种合欢皮新木脂体化合物,属于生物医药技术领域。
背景技术
合欢皮(Albiziae Cortex)是豆科植物合欢(Albzia julibrissin Durazz)的树皮,是一种较为常用的中药,性味甘、平,具有解郁、和血、宁心和消肿之功效。近年来,随着学者对合欢皮的深入研究,其化学成分和药理药效活性不断的被发现。
迄今为止,已从合欢属植物中分离出多种化合物,其中包括三萜、黄酮、木脂素类等。有文献表明,合欢皮中的木脂素类成分含量较低,对于综合评价合欢皮水溶性木脂素类成分的提取纯化工艺造成了一定的困难。同时,合欢皮常作为复方药物的一剂组分,极少单独应用,因而其含有的各类化学成分的药理活性尚不明确。
发明内容
本发明的第一个目的是提供一种合欢皮新木脂体化合物,其结构式如式1所示;
在一种实施方式中,所述化合物是式1所示化合物的药用盐或药用溶剂化物
本发明的第二个目的是提供含有所述化合物的组合物。
在一种实施方式中,所述组合物为药物组合物。
在一种实施方式中,所述组合物还含有药学上可接受的载体。
在一种实施方式中,所述药学上可接受的载体包括稀释剂、赋形剂或溶剂化物。
在一种实施方式中,所述药物组合物的剂型为片剂、胶囊、颗粒剂、散剂、糖浆剂、口服液或注射剂。
本发明的三个目的是提供一种制备式1所示化合物的方法,所述方法包括如下步骤:(1)将合欢皮用粉碎机粉碎,与浓度为70~80%的乙醇按照料液比为1:4~10的比例混合,70~90℃回流提取1~3次,每次1~3小时;(2)过滤除去合欢皮残渣,合并步骤(1)获得的提取液,冷冻干燥,收集粗提物,粉碎、混悬后依次用乙酸乙酯和正丁醇萃取;(3)回收正丁醇萃取液,干燥获得254g,采用D101大孔吸附树脂,用体积分数为30%、50%、70%和95%的乙醇进行洗脱分离,分别富集30%乙醇洗脱段、50%乙醇洗脱段、70%乙醇洗脱段、95%乙醇洗脱段;对30%乙醇洗脱段进行硅胶柱层析,采用40:1,20:1,16:1,10:1,8:1和6:1的二氯甲烷-甲醇混合液梯度洗脱,经TLC检测合并相同组分,收集10:1洗脱段。
在一种实施方式中,所述步骤(3)回收是在80℃减压旋蒸回收正丁醇,真空干燥箱干燥正丁醇萃取物。
本发明的第四个目的是提供所述化合物在制备预防或治疗脂代谢紊乱的药物中的应用。
本发明的第五个目的是提供所述化合物在制备促进内皮细胞增殖、迁移的药物中的应用。
本发明的第六个目的是提供所述化合物在制备抗氧化应激、保护内皮损伤的药物中的应用。
有益效果:本发明制备的化合物可有效治疗FFAs诱导的脂代谢紊乱及脂肪变性,在给药浓度为20μM,给药24h可以使脂滴面积减少约3倍;
本发明制备的化合物可显著增强HUVEC的细胞活性,并可显著促进细胞的自我复制,从而促进内皮细胞HUVEC增殖。在给药40μM,给药24h后,可使细胞活力为达到对照的242.233%。
本发明制备的化合物可显著抑制HUVEC细胞因HG诱导的活性氧簇(ROS)的产生,可使HG组平均荧光强度由818.37%降低至176.355%。
附图说明
图1为10:1洗脱段分析型高效液相色谱图。
图2为10:1组分Davisil C18反向柱42%CH3OH洗脱段半备型高效液相色谱图。
图3为化合物Aj4的1H-NMR色谱图。
图4为化合物Aj4的13C-NMR色谱图。
图5为albioside AR的HR-ESI-MS色谱图。
图6A为化合物albioside A抑制FFAs诱导的脂滴生成(×400);B为脂滴堆积面积值;其中,*P<0.05与对照组相比,#P<0.05与FFAs组相比,n=3/组。
图7为化合物albioside A促进细胞增殖活力,**P<0.01与对照组相比。
图8为化合物albioside A促进HUVEC细胞迁移。
图9为化合物albioside A增强HUVEC细胞的克隆即自我复制能力。
图10为化合物通过DCFH-DA荧光(×200)检测细胞内ROS水平;B.细胞内ROS荧光值。*P与对照相比P<0.05,与HG相比#P<0.05,n=3/组。
图11为8:1洗脱段分析型高效液相色谱图。
图12为8:1组分Davisil C18反向柱32%CH3OH洗脱段半备型高效液相色谱图。
图13为化合物Aj7的HR-ESI-MS色谱图。
图14为化合物Aj7的1H-NMR色谱图。
图15为化合物Aj7的13C-NMR色谱图。
具体实施方式
实施例1化合物的制备
(1)提取:取干燥合欢皮20kg,粉碎,用5倍75%乙醇(水)即每次100L,80℃回流提取2次,每次2小时。过滤除去合欢皮残渣,合并合欢皮75%乙醇提取液,冷冻干燥,得合欢皮乙醇粗提物1.6kg。将粗提物研碎,混悬于2L去离子水中,使其尽可能溶解。混悬后依次用乙酸乙酯及饱和正丁醇萃取,萃取采用每次添加乙酸乙酯和饱和正丁醇少量多次的原则,分别合并乙酸乙酯相及饱和正丁醇相的萃取液,得乙酸乙酯部位和正丁醇部位提取物。
(2)分离:取正丁醇部位254g,用去离子水溶解混悬,采用D101大孔吸附树脂进行分离纯化,分别用2~3倍柱体积的乙醇-水混合溶液为流动相进行梯度洗脱,富集30%乙醇洗脱段、50%乙醇洗脱段、70%乙醇洗脱段、95%乙醇洗脱段。大孔吸附树脂30%乙醇洗脱段经硅胶硅胶柱层析,以二氯甲烷-甲醇混合液为流动相,采用梯度溶剂二氯甲烷(CH2Cl2):甲醇(CH3OH)=(40:1,20:1,16:1,10:1,8:1和6:1)进行梯度洗脱(流动相体积为3倍柱体积,通过TLC实时检测是否获得目的产物),分别以4倍柱体积左右的流动相进行洗脱,用250ml锥形瓶分别收集洗脱液,经TLC检测合并相同组分,得各洗脱段。
对二氯甲烷(CH2Cl2):甲醇(CH3OH)溶剂10:1洗脱段进行分析型高效液相(HPLC)检测(色谱柱为X-Bridge C18,5μm,4.6×250mm,流速为1ml/min,柱温30℃),紫外检测波长为254nm,洗脱条件:
时间 CH3OH H2O
0min 5% 95%
60min 100% 0%
其结果如图1所示。根据图1液相检测条件下化合物的保留时间,确定硅胶10:1洗脱段的主要出峰在C18反向柱上的洗脱条件所对应的保留时间为23min,30min,36min,60min,且各保留时间所对应的甲醇浓度为41%CH3OH,52%CH3OH,62%CH3OH,100%CH3OH。
将10:1洗脱段过反向硅胶柱(Davisil C18,50μm),以甲醇和水为洗脱相进行洗脱。因为图1为分析型液相色谱图,色谱柱为X-Bridge C18(5μm,4.6×250mm),而DavisilC18反向柱填料为50μm,所以流动相甲醇浓度均减去10%。根据图1确定洗脱相组合为31%CH3OH,42%CH3OH,52%CH3OH,100%CH3OH.对洗脱组分分别进行HPLC检测,根据分析型液相摸索42%CH3OH洗脱段的分离条件,确定最佳分离条件,如表1所示。最后对42%CH3OH洗脱段进行半制备液相分离(色谱柱为X-Bridge C18,5μm,10×250mm,流速为4ml/min,柱温30℃),其结果如图2所示,保留时间t=26.50min处的化合物命名为albiosideA(Aj4)。
表1半制备液相色谱的不同分离条件
在表1所示的分离条件中,条件一、条件二及条件三无法有效分离Aj4,其保留时间附近具有杂峰干扰,分离条件四可较为有效分离化合物Aj4,本实验采用的分离条件在条件四的基础上进一步优化的最佳分离方法,其分离效果如图2所示。收集保留时间t R=26.50min处的化合物,75℃减压旋蒸,回收溶剂,真空干燥箱干燥得Aj4单体化合物。
(3)结构鉴定(图3~5所示):Aj4为淡黄色粉末,通过UPLC-ESI-MS检测,ESI-MS m/z 633.1932[M+Cl-],通过Monoisotopic Mass,Even Electron Ions确定其分子式为C28H38O14。
将样品Aj4用氘代甲醇溶解于核磁管中,采用全数字化核磁共振波谱仪测定1HNMR、13CNMR,其结果如下:
1H NMR(400MHz,CD3OD)δ6.76(2H,s,H-2’,6’),6.74(2H,s,H-2,6),6.56(1H,d,J=16.0Hz,H-7’),6.34(1H,dt,J=15.8,5.5Hz,H-8’),4.81(1H,d,J=7.2Hz,H-7),4.65(4H,s),4.29(1H,dd,J=9.0,4.8Hz,H-1”),4.24(2H,d,J=5.4Hz,H-9’),3.96–3.88(2H,m),3.85(6H,s,3,5-OMe),3.83(6H,s,3’,5’-OMe),3.77(1H,s),3.73–3.63(4H,m),3.60(1H,dd,J=8.4,3.9Hz),3.56–3.39(4H,m),3.22(s,1H).13C NMR(101MHz,CD3OD)δ153.08(C-3’,5’),152.39(C-3,5),138.12(C-4’),134.99(C-4),134.13(C-1’),133.30(C-1),129.95(C-7’),128.51(C-8’),104.62(C-2,6),104.26(C-1”),103.51(C-2’,6’),85.66(C-8),76.94(C-3”),76.37(C-5”),74.32(C-2”),72.64(C-7),69.92(C-4”),62.16(C-9),61.17(C-9’),60.23(C-6”),55.61(3’,5’-OMe),55.28(3,5-OMe)。
根据质谱及1HNMR、13CNMR最终确定其结构如下,化学名2-[4-(3-Hydroxy-1-propenyl)-2,6-dimethoxy-phenoxy]-3-hydroxy-3-(4-hydroxy-3,5-dimethoxy-ph enyl)propyl-β-D-glucopyranoside.对其命名为合欢新木脂苷A(albiosideA,Aj4)。
实施例2改善脂代谢紊乱及脂肪变性
在含有25%葡萄糖、10%FBS(胎牛血清、Gibco)、100U/ml青霉素和100/ml链霉素的DMEM中培养HepG2细胞(American Type Culture collection,USA)。在含有5%CO2的37℃恒温培养箱中培养。每1-2天更换培养基,将85-90%汇合的细胞以1:3汇合的比例传代。在所有实验中,细胞在第2代和第5代之间使用。取对数生长期的HepG2细胞,铺12孔板,每孔铺10万。待12h细胞贴壁生长后,弃去正常DMEM培养基,加入含有0.3mM FFAs(油酸:棕榈酸=2:1,其中油酸用DMSO溶解,棕榈酸用超纯水75℃水浴溶解成40mM的溶解,在迅速与40%BSA的PBS溶解混匀,冷却过0.22μm无菌滤膜,用DMEM培养基稀释成0.3mM FFAs高脂培养基)的DMEM高脂培养基继续培养24h,即HepG2细胞被造模成为脂代谢紊乱模型后,每孔加入实施例1制备的化合物,给药浓度设置5个浓度梯度(其中以正常培养基培养的HepG2细胞为对照,对照组加相同体积的PBS作为空白对照组),其余以5μM、10μM、20μM、40μM、80μM的终浓度(albioside A用DMSO溶解成100mM,再分别用无菌PBS稀释,最后每孔加入20μL高浓度单体药物,使培养基终浓度为所设置浓度梯度)继续培养24h。
弃去12孔板的培养基,用PBS洗三遍,4%多聚甲醛固定30min,固定结束后以PBS充分洗涤,随后以60%异丙醇浸洗10~15秒,再以PBS洗三遍。以油红O染液(油红储存液:去离子水=3:2)室温染色20~30min,显微镜下观察细胞着色情况,弃去油红染液,以60%异丙醇分化至间质清晰(分化约5~10秒即可,分化过度会导致油红O褪色),最后以PBS洗三遍,每孔加1ml PBS封片、拍照。
油红O染色结果如图6,与空白对照组脂滴面积100%相比,FFAs可显著诱导HepG2细胞脂滴累积及脂肪变性,此时脂滴面积与空白对照组相比平均为988.23%(*P<0.05,n=3/组),当给药24h后,给药浓度为10μM时,albioside A可有效减少脂滴的生成,当给药浓度为20μM时,与空白对照组相比脂滴平均面积为240.165%(与FFAs诱导组相比#P<0.05,n=3/组),说明albioside A可有效治疗FFAs诱导的脂代谢紊乱及脂肪变性。其中图6B,脂质堆积面积值使用Image-Pro Plus 6.0软件在相同参数下进行处理。
肝脂肪变性是2型糖尿病(T2DM)的显著特征,可能导致非酒精性脂肪肝疾病和心血管疾病。本实施例说明albioside A可有效治疗FFAs诱导的脂代谢紊乱及脂肪变性,可作为治疗非酒精性脂肪肝及相关肝细胞病变的潜在的天然药物,也可作为预防2型糖尿病及心血管疾病药物。
实施例3促进内皮细胞增殖活性
人脐静脉内皮细胞(HUVECs)用含有10%FBS和1%青霉素/链霉素的DMEM培养基,在含有5%CO2的37℃恒温培养箱中培养。每1-2天更换培养基,将85-90%汇合的细胞以1:3汇合的比例传代。在所有实验中,细胞在第2代和第5代之间使用。取对数生长期的HUVEC细胞,铺96孔板,每孔加100μL培养基,铺3000个细胞。12小时贴壁后给药,继续培养24h,随后每孔加10μL CCK-8,37℃细胞培养箱孵化1h后,用酶标仪在450nm波长处检测吸光度(OD)值,计算细胞活力。
结果如图7所示,空白对照组相比,给药24h后,HUVEC细胞活力均明显增高,在本实验中当给药40μM时,与空白对照组100%相比,细胞活力为242.233%,说明albioside A可显著增强HUVEC的细胞增殖活力。
治疗性血管新生是指将外源性血管新生诱导因子转入组织中,促进缺血区侧支毛细血管新生,是近年来治疗局部缺血性疾病的重要方法。血管新生过程与血管内皮细胞迁移和增殖密切相关,结果显示albioside A可有效促进内皮细胞迁移,增强细胞活力及自我复制的能力,也即可有效促进血管新生。
实施例4促进HUVEC细胞迁移
人脐静脉内皮细胞(HUVECs)在含有10%FBS和1%青霉素/链霉素的DMEM中,在含有5%CO2的37℃恒温培养箱中培养。每1-2天更换培养基,将85-90%汇合的细胞以1:3汇合的比例传代。在所有实验中,细胞在第2代和第5代之间使用。取对数生长期的HUVEC细胞,铺6孔板,每孔铺20万,培养24小时即细胞贴壁后,对皿中细胞进行划痕,随后用PBS洗2遍,加入培养基(含有40μM的albioside A单体化合物)继续培养24小时,观察细胞迁移状态。实验结果表明,albioside A可显著促进细胞迁移,其结果如图8所示,划痕后,给药40μM继续培养24h,倒置显微镜拍照,albioside A可显著促进细胞迁移,在体内实验中也即是促进伤口愈合的作用。
实施例5克隆实验
人脐静脉内皮细胞(HUVECs)在含有10%FBS和1%青霉素/链霉素的DMEM中,在含有5%CO2的37℃恒温培养箱中培养。每1-2天更换培养基,将85-90%汇合的细胞以1:3汇合的比例传代。在所有实验中,细胞在第2代和第5代之间使用。取对数生长期的HUVEC细胞,用胰酶消化并吹打成单个细胞,铺6孔板,每孔加2ml培养基,每孔接种100个细胞,置37℃含5%CO2的细胞培养箱培养。当培养皿中出现肉眼可见的克隆时,终止培养。弃去上清液,用PBS小心浸洗2次。加4%多聚甲醛固定15分钟。然后去固定液,加适量GIMSA应用染色液染10—30分钟,然后用流水缓慢洗去染色液,空气干燥。最后观察克隆数,其结果如图9,给药组克隆数明显多于对照组,其结果表明单体化合物albioside A可显著促进细胞的自我复制,从而促进内皮细胞HUVEC增殖也即血管新生。
实施例6抗氧化应激
人脐静脉内皮细胞(HUVECs)在含有10%FBS和1%青霉素/链霉素的DMEM中,在含有5%CO2的37℃恒温培养箱中培养。每1-2天更换培养基,将85-90%汇合的细胞以1:3汇合的比例传代。在所有实验中,细胞在第2代和第5代之间使用。为了检测合欢皮木脂苷A(Albioside A)在高浓度葡萄糖(HG)诱导HUVEC细胞氧化应激中的保护作用,取对数生长期的HUVEC细胞,铺12孔板,待12h细胞贴壁后,加入80μM的albioside A继续培养12h(设置5个复孔),随后加预先配好的无菌葡萄糖溶液(葡萄糖用PBS溶解后,过0.22μm无菌滤膜,然后每孔加入50μL高浓度葡萄糖溶液,空白对照组加50μLPBS),使得终浓度为35mM,继续培养24h。通过荧光探针DCFH-DA检测细胞内ROS的产生。用PBS洗涤HUVEC3次,然后用10μM的DCFH-DA(DCFH-DA定溶于PBS)在37℃避光条件中孵育30分钟。用PBS洗涤细胞后,在荧光显微镜(80i,Nikon,Japan)上拍照。
其结果如图10所示,与Control组ROS荧光强度100%相比,35mM的HG显著增加HUVEC细胞活性氧的累积也即促进内皮损伤,此时ROS荧光强度为818.37(*P<0.05vs.Control,n=3/组)。当用80μM的albioside A处理时24h后吗,其荧光强度为176.335((#P<0.05vs.HG,n=3/组))实验表明HUVEC细胞暴露于HG增加了活性氧的积累,DCFH-DA染色结果显示albioside A消除了HG诱导的活性氧产生,当用80μM处理时,ROS积累显著减少。其中图10B,荧光平均强度值使用Image-Pro Plus 6.0软件在相同参数下进行处理。
由于累积的活性氧簇(ROS)是对高葡萄糖(High glucose or HG)的反应,也是细胞损伤和细胞凋亡的主要原因。现有研究表明活性氧在HG诱导的内皮细胞凋亡中起主要作用。高血糖症是糖尿病中最重要的特征之一,其导致各种心血管并发症。高血糖对心血管系统的不良反应机制复杂,其中活性氧参与高血糖引起的心血管损伤的发病机制,持续高血糖可引起活性氧生成及内皮细胞功能障碍。结果显示HG可显著诱导内皮细胞损伤,ROS累积,albioside A可显著清除累积的ROS,保护高糖诱导的内皮细胞损伤,也表明可作为治疗糖尿病等并发症的潜在药物。
对比例1:
具体实施方式同实施例1,区别在于,对硅胶8:1洗脱段进行分析型高效液相(HPLC)检测(色谱柱为X-Bridge C18,5μm,4.6×250mm,流速为1ml/min,柱温30℃),紫外检测波长为254nm,
洗脱条件:CH3OH H2O
0min 5% 95%
60min 100% 0%。
其检测结果如图11所示,根据图11的分析型高效液相色谱图中各组分的保留时间,确定对CH2Cl2:CH3OH=8:1洗脱段进行过反向硅胶柱(Davisil C18,50μm)的洗脱条件为tR=22min、24min、26min,60min时所对应的CH3OH浓度39.8%、42.9%、46.2%、100%,因为图11为分析型液相色谱图,色谱柱为X-Bridge C18(5μm,4.6×250mm),而Davisil C18反向柱填料为50μm,所以流动相甲醇浓度均减去10%,即29.8%、32.9%,36.2%,100%。以甲醇和水为洗脱相进行洗脱。根据图11确定洗脱相组合为29%CH3OH(H2O),32%CH3OH(H2O),36%CH3OH(H2O),100%CH3OH.对32%CH3OH洗脱组分进行分析型HPLC检测,摸索分离条件,以确定最佳分离方法(如表二所示)。对32%CH3OH洗脱段进行半制备液相分离(色谱柱为X-Bridge C18,5μm,10×250mm,流速为4ml/min,柱温30℃),如图12所示(UV检测波长290nm),保留时间tR=41.0min处的化合物为迭鞘石斛C(Picraquassioside C)(Aj7),
Aj7为白色粉末,通过UPLC-ESI-MS检测,其质谱图如图13所示。HR-ESI-MS m/z633.1688[M+Cl]-,通过Monoisotopic Mass,Even Electron Ions确定其分子式为C28H38O14。将样品Aj7用氘代甲醇溶解于核磁管中,采用全数字化核磁共振波谱仪测定1H-NMR、13C-NMR,其结果如下:
1H-NMR(400MHz,CD3OD)δ6.76(2H,s,H-2,6),6.74(2H,s,H-2’,6’),6.57(1H,d,J=15.8Hz,H-7’),6.33(1H,dt,J=15.8,5.5Hz,H-8’),4.94(1H,d,J=5.6Hz,H-7),4.81(1H,d,J=7.3Hz,H-1”),4.29(1H,dd,J=9.0,4.8Hz,H-8),4.24(1H,d,J=5.4Hz,H-9’),3.98–3.89(2H,m),3.87(1H,s),3.85(6H,s,3,5-OMe),3.83(6H,s,3’,5’-OMe),3.77(1H,s),3.73–3.58(4H,m),3.52–3.41(4H,m),3.37(1H,s),3.22(s,2H).13C-NMR(101MHz,CD3OD)δ153.09(C-3’,5’),152.40(C-3,5),138.12(C-1),135.02(C-4’),134.17(C-4),133.31(C-1’),129.96(C-8’),128.53(C-7’),104.66(C-2,6),104.29(C-1”),103.55(C-2’,6’),85.68(C-8),76.94(C-5”),76.39(C-3”),74.34(C-2”),72.67(C-7),69.95(C-4”),62.17(C-9’),61.20(C-6”),60.25(C-9),55.63(3,5-OMe),55.31(3’,5’-OMe).
根据质谱及1HNMR、13CNMR最终确定其结构如下,中文名为迭鞘石斛C,英文名Picraquassioside C,与合欢新木脂苷A(albioside A)为互为同分异构体。
对比例2:
具体实施方式同实施例2~6,区别在于,将albioside A替换成迭鞘石斛C,虽然两者互为为同分异构体,结构类似,但迭鞘石斛C并不具有促进内皮血管新生、改善脂肪变性、抗氧化应激的药理活性。
虽然本发明已以较佳实施例公开如上,但其并非用以限定本发明,任何熟悉此技术的人,在不脱离本发明的精神和范围内,都可做各种的改动与修饰,因此本发明的保护范围应该以权利要求书所界定的为准。
Claims (6)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910945573.4A CN110590873B (zh) | 2019-09-30 | 2019-09-30 | 一种合欢皮新木脂体化合物 |
PCT/CN2020/102544 WO2021063075A1 (zh) | 2019-09-30 | 2020-07-17 | 合欢皮木脂体化合物及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910945573.4A CN110590873B (zh) | 2019-09-30 | 2019-09-30 | 一种合欢皮新木脂体化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110590873A CN110590873A (zh) | 2019-12-20 |
CN110590873B true CN110590873B (zh) | 2020-12-01 |
Family
ID=68865464
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910945573.4A Active CN110590873B (zh) | 2019-09-30 | 2019-09-30 | 一种合欢皮新木脂体化合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110590873B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110638821A (zh) * | 2019-09-30 | 2020-01-03 | 江南大学 | 一种具有抗氧化活性的合欢皮新木脂体化合物及其应用 |
CN111110687A (zh) * | 2019-09-30 | 2020-05-08 | 江南大学 | 一种抗脂代谢紊乱的合欢皮新木脂体化合物 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021063075A1 (zh) * | 2019-09-30 | 2021-04-08 | 江南大学 | 合欢皮木脂体化合物及应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104151373B (zh) * | 2013-05-13 | 2017-01-18 | 四川万安石斛产业开发有限公司 | 一种木脂素苷类化合物及其制备方法 |
KR20160050191A (ko) * | 2014-10-28 | 2016-05-11 | 한국콜마주식회사 | 신규 네오리그난 화합물 |
CN105030802B (zh) * | 2015-06-27 | 2020-07-07 | 海南医学院 | 一种木脂素类化合物的应用 |
-
2019
- 2019-09-30 CN CN201910945573.4A patent/CN110590873B/zh active Active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110638821A (zh) * | 2019-09-30 | 2020-01-03 | 江南大学 | 一种具有抗氧化活性的合欢皮新木脂体化合物及其应用 |
CN111110687A (zh) * | 2019-09-30 | 2020-05-08 | 江南大学 | 一种抗脂代谢紊乱的合欢皮新木脂体化合物 |
Also Published As
Publication number | Publication date |
---|---|
CN110590873A (zh) | 2019-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110590873B (zh) | 一种合欢皮新木脂体化合物 | |
CN105582000B (zh) | 杜仲皮或杜仲叶中萜类物质在制备治疗老年性痴呆或阿尔茨海默病药物中的应用 | |
CN110563781B (zh) | 一种合欢皮新木脂体单体化合物的制备方法 | |
CN113105388B (zh) | 一种千金二萜烷化合物及其提取方法和应用 | |
CN108610387B (zh) | 一种具有神经细胞保护活性的四个异黄烷苷类化合物及其制备方法 | |
WO2022257995A1 (zh) | 一种隐丹参酮衍生物及其制备方法和降脂抗肥胖的应用 | |
CN104926825A (zh) | 促进神经营养活性的新木脂烷衍生物及其制备方法与应用 | |
WO2004039759A1 (fr) | Compose naturel servant dans le traitement de diabetes, sa preparation et son utilisation | |
CN104945361B (zh) | 吉玛烷型倍半萜衍生物及其制备方法与应用 | |
CN115521245B (zh) | 马齿苋中一种生物碱类化合物及其提取分离方法与应用 | |
CN110638822A (zh) | 一种促进内皮细胞增殖的合欢皮木脂素苷类化合物及应用 | |
CN105884720A (zh) | 一种盐酸丁螺环酮的药物组合物及其医药用途 | |
CN110559307A (zh) | 一种合欢皮新木脂体化合物及其新用途 | |
CN111110687A (zh) | 一种抗脂代谢紊乱的合欢皮新木脂体化合物 | |
CN110638821A (zh) | 一种具有抗氧化活性的合欢皮新木脂体化合物及其应用 | |
CN103626812A (zh) | 天麻中一种新的巴利森苷类化合物及其用途 | |
CN110585221A (zh) | 一种改善脂肪变性的合欢皮新木脂体化合物及其应用 | |
WO2021063075A1 (zh) | 合欢皮木脂体化合物及应用 | |
CN112851612A (zh) | 一种从牛蒡叶中提取的具有降低胆固醇活性化合物及其制备方法与应用 | |
WO2021063076A1 (zh) | 合欢皮木脂体化合物在改善脂肪变性方面的应用 | |
CN111812252B (zh) | 一种对植物中降糖功能化合物的筛选及分离方法 | |
CN110885385B (zh) | 翼首草毒素a及其应用和低肝损伤毒性翼首草提取物的制备方法 | |
CN115073463B (zh) | 一类苦参碱型二聚体生物碱类化合物、其药物组合物及其应用 | |
CN114656393B (zh) | 一种吡咯-2-醛类化合物及其制备方法和应用 | |
CN110204477B (zh) | 一种具有抗氧化作用的二萜生物碱及其在制备药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: No. 1800 road 214000 Jiangsu Lihu Binhu District City of Wuxi Province Applicant after: Jiangnan University Address before: 214000 Zhang Yong, 1800 Lihu Avenue, Binhu District, Wuxi City, Jiangsu Province Applicant before: Jiangnan University |
|
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |